Drift, evolution, and divergence in biologics and biosimilars manufacturing

Area of Science:

• Biotechnology
• Pharmaceutical Sciences
• Regulatory Science

Background:

• Biological medicines (biologics) are complex products manufactured using living cells, making them sensitive to process variations.
• Ensuring consistent quality, safety, and efficacy of biologics relies heavily on rigorous manufacturing process control and robust quality systems.
• The advent of biosimilars introduces multiple manufacturers, each with potentially different quality systems, increasing the complexity of product consistency.

Purpose of the Study:

• To define and differentiate product drift, evolution, and divergence in the context of biologic manufacturing.
• To explore the potential impact of these phenomena on the quality, safety, efficacy, and interchangeability of biologics, particularly with biosimilar competition.
• To propose strategies for minimizing the risks associated with biologic product divergence.

Main Methods:

• Conceptual analysis of manufacturing processes, quality systems, and product attributes for biologics.
• Review of potential impacts of process deviations and changes on biologic characteristics.
• Examination of the implications of multiple manufacturers and differing quality systems on product consistency over time.

Main Results:

• Product drift (unintended attribute changes), evolution (shifts due to known changes), and divergence (cumulative differences over time) are distinct but related concepts.
• Minor quality system changes can lead to product drift, potentially affecting safety and efficacy.
• Divergence among originator and biosimilar biologics, and even among originator products, is a potential outcome of differing manufacturing and quality systems.

Conclusions:

• Robust quality systems are essential for detecting and mitigating biologic product drift.
• Thorough evaluation of product evolution resulting from manufacturing changes is necessary to ensure safety and efficacy.
• Minimizing divergence requires strong pharmacovigilance, clear biologic naming conventions, high interchangeability standards, and accurate medical record-keeping.